Tous Actualités
Suivre
Abonner Baxter International Inc.

Baxter International Inc.

Baxter Suspends Enrollment in European Clinical Trial for PreFluCel

Deerfield, Illinois (ots/PRNewswire)

Baxter International Inc.
(NYSE: BAX) announced today that it has voluntarily suspended
enrollment in the Phase II/III clinical study currently underway in
Europe of its PreFluCel influenza vaccine, due to a higher than
expected rate of mild fever and associated symptoms in the clinical
trial participants.
"In developing a vaccine, we aim to achieve a high level of
efficacy while minimizing potential side effects," said Norbert G.
Riedel, Baxter's chief scientific officer. "Based on the preliminary
data we've seen, the rate of fever and associated symptoms observed
with the current formulation of PreFluCel is higher compared to other
vaccines available on the market."
Baxter has put further clinical studies planned for 2005 on hold
while the company continues to analyze the data from this clinical
trial.
Baxter International Inc., through its subsidiaries, assists
health-care professionals and their patients with the treatment of
complex medical conditions, including cancer, hemophilia, immune
disorders, kidney disease and trauma. The company applies its
expertise in medical devices, pharmaceuticals and biotechnology to
make a meaningful difference in patients' lives.
Web site: http://www.baxter.com

Contact:

Media, Deborah Spak, +1-847-948-2349, or Cindy Resman,
+1-847-948-2815; or Investors, Mary Kay Ladone, +1-847-948-3371, Mike
Shapiro, +1-847-948-3212, all of Baxter International Inc.

Plus de actualités: Baxter International Inc.
Plus de actualités: Baxter International Inc.